EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety

Chiara Burgio iD, Maria D Giron iD, Mariano Ortega-Muñoz, Daniel Lucena iD, Rafael Salto iD

Biomacromolecules · 27.06.2026

DOI: 10.1021/acs.biomac.6c00502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 27.06.2026. Verfasst von Chiara Burgio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Granada E-18071, Spain. Hauptthemen laut MEDLINE: Galectin 3, Protein Engineering, Theranostic Nanomedicine, Drug Delivery Systems. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Junta de Andaluc?a.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High Resolution Image Download MS PowerPoint Slide To generate drug-targeting agents with a modular and efficient design for disease treatments, including cancer, we used protein coil-coiled dimerization motifs to eliminate the need for chemical conjugation techniques, generating a versatile theranostic system: a targeting moiety genetically fused to an E 3 coil and a fusion protein of maltose-binding protein and a monomeric streptavidin that includes a K 3 coil. The system can be directed to other targets by changing the targeting moiety. The second component enables simultaneous binding to two different ligands (maltosylated or biotinylated). We tested the system using a truncated human Galectin-3 as the targeting moiety, which binds to β-galactoside-containing oligosaccharides overexpressed on the plasma membranes of tumor cells, and biotinylated doxorubicin as the cargo molecule. In vitro experiments using cell lines that express or do not express Galectin-3 ligands and in vivo mouse xenografts demonstrated the system’s capability, specificity, and flexibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3Protein EngineeringTheranostic NanomedicineDrug Delivery SystemsHumansAnimalsMiceDoxorubicinCell Line, TumorBlood ProteinsGalactosidesRecombinant Fusion ProteinsMaltose-Binding ProteinsGalectinsStreptavidin

Substanzen

Galectin 3LGALS3 protein, humanDoxorubicinbeta-galactosideBlood ProteinsGalactosidesRecombinant Fusion ProteinsMaltose-Binding ProteinsGalectinsStreptavidin

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Granada E-18071, Spain.
  • Unit of Excellence in Chemistry Applied to Biomedicine and the Environment of the University of Granada, Granada E-18071, Spain.
  • Department of Organic Chemistry, School of Sciences, Biotechnology Institute, University of Granada, Granada, E-18071 Spain.

ORCID-Profile: Chiara Burgio, Maria D Giron, Daniel Lucena, Rafael Salto

Förderung

  • Junta de Andaluc?a

Zitieren

APA

Burgio, C., Giron, M. D., Ortega-Muñoz, M., Lucena, D., & Salto, R. (2026). Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules. https://doi.org/10.1021/acs.biomac.6c00502

Vancouver

Burgio C, Giron MD, Ortega-Muñoz M, Lucena D, Salto R. Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules. 2026. doi:10.1021/acs.biomac.6c00502

BibTeX
@article{Burgio2026,
  author = {Burgio, Chiara and Giron, Maria D and Ortega-Muñoz, Mariano and Lucena, Daniel and Salto, Rafael},
  title = {Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety},
  journal = {Biomacromolecules},
  year = {2026},
  doi = {10.1021/acs.biomac.6c00502}
}
Kostenlos starten →